Changes in interleukin-1 beta induced by rTMS are significantly correlated with partial improvement of cognitive dysfunction in treatment-resistant depression: a pilot study
Changes in interleukin-1 beta induced by rTMS are significantly correlated with partial improvement of cognitive dysfunction in treatment-resistant depression: a pilot study
复制标题
DOI：
10.1016/j.psychres.2020.112995
复制
发表时间：
2020-04
影响因子：
11.3
通讯作者：
H. Tateishi;Y. Mizoguchi;A. Kawaguchi;Yoshiomi Imamura;Jun Matsushima;H. Kunitake;Toru Murakawa;Y. Haraguchi;Yutaka Kunitake;T. Maekawa;Takahiro A. Kato;T. Asami;A. Monji
中科院分区：
文献类型：
--
作者：
H. Tateishi;Y. Mizoguchi;A. Kawaguchi;Yoshiomi Imamura;Jun Matsushima;H. Kunitake;Toru Murakawa;Y. Haraguchi;Yutaka Kunitake;T. Maekawa;Takahiro A. Kato;T. Asami;A. Monji
许多抑郁症患者所经历的损害与该障碍的认知症状密切相关。重复经颅磁刺激(RTMS)是一种无创的脑刺激方法，为改善难治性抑郁症(TRD)的认知症状提供了一种有前途的技术。最近的研究表明，TRD与炎症过程的增加有关。在目前的研究中，我们调查了rTMS治疗前后认知功能的变化和炎性细胞因子的变化之间是否存在关系。11名TRD患者参加了高频(10赫兹)rTMS研究。分别于治疗前和治疗结束时检测认知功能、抑郁症状和血清炎症细胞因子(IL-1β、IL-6和肿瘤坏死因子-α)浓度。RTMS治疗可显著改善抑郁症状评分和认知功能障碍的部分分量表。目前的研究表明，认知功能的部分变化与IL-1β的变化显著相关。在本研究中，rTMS对认知功能障碍的部分改善可能是由于降低了外周血IL-1β水平。目前的结果应在今后的研究中重复验证。
The impairment experienced by many individuals with depression is closely related to the cognitive symptoms of the disorder. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive brain stimulation method that provides a promising technique for improving cognitive symptoms in treatment-resistant depression (TRD). It has recently been demonstrated that TRD is associated with increased inflammatory process. In the present study, we investigated whether a relationship exists between changes in cognitive function and those in inflammatory cytokines before and after rTMS treatment. Eleven patients with TRD were enrolled in a high-frequency (10 Hz) rTMS study. Cognitive function, depressive symptoms and serum concentration of inflammatory cytokines (interleukin (IL)-1β, IL-6 and tumor necrosis factor-α) were measured at baseline and at the endpoint of rTMS treatment. rTMS treatment significantly improved depressive symptom scores and some subscales of cognitive dysfunction. The present study has demonstrated that partial changes in cognitive function and changes in IL-1β were significantly correlated. The partial improvement of cognitive dysfunction by rTMS in the present study might be attributable to the reduction of peripheral IL-1β levels. The present results should be replicated for verification in future studies.